Latest nausea Stories
WOODCLIFF LAKE, N.J., Aug. 23 /PRNewswire/ -- Eisai Corporation of North America and its partner Helsinn Healthcare SA today announced that the U.S.
MOUNTAIN VIEW, Calif., July 14 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. today announced it has initiated its Phase 3 clinical program to evaluate MAP0004 as a potential treatment for migraine.
Merck & Co., Inc.
Merck & Co., Inc. announced today that the US Food and Drug Administration (FDA) has issued a complete response letter regarding the supplemental biologics license application (sBLA) for the use of GARDASIL(R) in women ages 27 though 45.
AP Pharma has completed patient enrollment in its pivotal Phase III study in chemotherapy-induced nausea and vomiting comparing the efficacy of APF530 with Aloxi for the prevention of acute and delayed onset chemotherapy-induced nausea and vomiting in both moderate and highly emetogenic chemotherapy treatments.
A new study from the Monell Center increases understanding of the biological mechanisms responsible for the nausea and vomiting that often afflict patients undergoing chemotherapy. The findings could lead to the development of new approaches to combat these debilitating side effects.
Merck & Co., Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved EMEND(R) (fosaprepitant dimeglumine) for Injection, a new intravenous therapy for the prevention of chemotherapy-induced nausea and vomiting (CINV).
NuPathe Inc., a privately held specialty pharmaceutical company developing innovative products for the treatment of neurological and psychiatric diseases, today announced that George Moonsammy, Ph.D. has been appointed Vice President of Development. Dr.
By Kutlu, Tayfun; Tugrul, Semih; Aydin, Arzu; Oral, zay Hyperemesis gravidarum is a severe and intractable form of nausea and vomiting in pregnancy. The peak incidence is at 8-12 weeks of pregnancy, and symptoms usually resolve by week 16.
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.